Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

Moderna is down 35.3% since the beginning of the year, and at $27.16 per share, it is trading 50.3% below its 52-week high of ...

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their ...

A social media giant faltered on Thursday, Oct. 30, 2025, as a tax event weighed on its results, while a biotech name benefitted from reports of talks with a major pharma player.

Nasdaq rises as Amazon and Nvidia fuel AI optimism; tech stocks gain while broader US indices trade mixed, highlighting weak market breadth today.

The major stock indexes were mixed on Monday, at the outset of another busy week of quarterly earnings reports and the release of key private sector employment data.

The Federal Reserve officials cut interest rates by 25 basis points on Wednesday, pushing Treasury yields (^FVX, ^TNX, ^TYX) ...